NasdaqGS:IMCRBiotechs
How Investors May Respond To Immunocore (IMCR) Melanoma Data Highlighting Brenetafusp’s Potential In PD‑1‑Resistant Disease
Immunocore Holdings plc recently reported updated Phase 1/2 data for its bispecific T cell receptor therapy brenetafusp in heavily pretreated advanced melanoma at the 2026 American Society of Clinical Oncology Annual Meeting, showing encouraging disease control and six‑month survival in patients with limited treatment options.
The consistency of responses even in poor‑prognosis groups, including those with primary PD‑1 resistance, is strengthening confidence in the ongoing Phase 3...